"Initially, ChemDiv will be responsible for the design ofthe screening library. Novartis will screen the ChemDiv compounds in itsultra-high-throughput platform in Singapore on Mycobacteria," says Konarkowski."ChemDiv has produced some novel chemotypes, and synthesized particularlibraries around them, it believes has higher chances to work against evenmulti-resistant stems. NITD has great experience in biological
in-vitro and
in-vivo models for the preclinical development, whereas ChemDiv ResearchInstitute at ChemRar High Tech Centre (the contractual party) will use itsexpertise in medicinal chemistry to move active compounds forward."
The collaboration was launched by a memorandum ofunderstanding that was signed in September 2010, when a Russian governmentdelegation visited Singapore. The memorandum was endorsed and supported byNovartis, and it is expected to also receive support in Russia from theMinistry of Industry and Trade as well as the Ministry of Health and Socialdevelopment. According to Konarkowski, "Deputy Minister Denis Manturov of theRussian Ministry for Industry and Trade was present at the signing of the[memorandum of understanding] at NITD between Novartis Head of Research PaulHermann and ChemRar Chairman of the Board Andrey Ivashchenko."
Jeffrey Lockwood, a spokesman for the
Novartis Institutesfor BioMedical Research, says the CDRI appealed to Novartis as a partnerbecause "ChemRar is an established chemical service provider and has a librarycomprised of more than fifty thousand semi-natural compounds ready to bescreened."
"We are honored to commit our research platforms andsignificant experience in novel anti-infective drug discovery to such a noblecause," Nikolay Savchuk, chairman of the board of CDRI, said in a pressrelease. "We are delighted to participate in an innovative Public PrivatePartnership, endorsed by the governments of Singapore and Russia, to work ontheir national priorities to aid the world in the battle against tuberculosis.Our chemical expertise combined with Novartis' commitment to discovering anddeveloping medicines for diseases of the developing world creates uniquesynergy that will help patients around the globe."
"NITD is a world leader in anti-TB research," addsKonarkowski. "In addition, Novartis has great experience in commercializingdrugs in world markets, and also serves the non-for-profit regions ofsub-Saharan Africa and Asia."
Tuberculosis remains a prominent health problem today,accounting for nearly 2 million deaths per year worldwide. One-third of theworld's population is infected with latent tuberculosis, and approximately 5 to10 percent of those infected may develop active tuberculosis. The current formof tuberculosis treatment takes more than six months, and multi-drug resistanttuberculosis and tuberculosis co-infection with HIV are both increasing theneed for new drugs. On a
World Health Organization list of countries with riskof tuberculosis, Russia ranks seventh, Konarkowski notes.
This person does not yet have a bio.View Full Profile
